Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.
Finasteride can help maintain hair and slow hair loss, but its effectiveness varies by individual. Some may switch to dutasteride or add minoxidil for better results, though side effects are a concern.
Rhamnose may promote hair growth and pigmentation, suggesting it as a potential hair loss treatment. The conversation discusses its potential alongside known treatments like Minoxidil, finasteride, and RU58841.
High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.
Hair regrowth treatment involving 3aHSD enzyme shows 6% improvement in 18 weeks. Sulforaphane, L-Menthol, and Dexpanthenol are potential ingredients for new hair loss solution.
New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.
The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
Melatonin's effect on aromatase expression is unclear, with studies showing both increases and decreases. Hormonal impacts are complex and inconsistent, similar to changing health advice on other substances.
The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.
Stress can lead to hair loss by affecting hair-follicle stem cells, and this loss is harder to recover from if one has male pattern baldness (MPB). Treatments like finasteride and minoxidil are used to address hair loss, but stress-related hair loss differs from androgenic alopecia.
The post discusses the potential of upregulating aromatase to treat hair loss, suggesting that increasing CCL2 levels through Vitamin D or microneedling might help. The user questions why microneedling doesn't work for everyone, especially those with advanced hair loss.
A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.
GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.
A user is considering switching from oral to topical finasteride to reduce systemic DHT impact and is exploring ethossomal finasteride for better skin penetration and potential hair regrowth. They found ethossomal finasteride in Brazil and are seeking opinions on its effectiveness compared to other topical delivery methods.
A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.
DHT causes hair loss by driving cells into senescence, and a polyphenol in black chokeberry may reverse this. A product using this theory is being considered for use alongside finasteride, minoxidil, and microneedling.
Some hair loss may be linked to chromosome 20, which isn't affected by DHT blockers like finasteride. Treatments like minoxidil, microneedling, and genetic testing are suggested, but their effectiveness for this type of hair loss is uncertain.
Corticosterone inhibits GAS6, affecting hair follicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.
The conversation discusses the potential role of prolactin in hair loss and mentions treatments like HMI115, mucuna pruriens, Zinc, and B6 P5P for lowering prolactin levels. It also touches on the use of natural compounds and the lack of studies due to funding issues.
The conversation discusses using TH16, a topical melatonin with resveratrol, and stemoxydine for hair maintenance, avoiding finasteride and minoxidil due to side effects. The user is considering a low-dose topical finasteride despite sensitivity.
The conversation is about the effectiveness of Stemoxydine for hair loss. The user reports reduced hair shedding after one week but also a more noticeably thinned scalp.
The conversation is about creating homemade topical melatonin for hair loss, with one person suggesting adding melatonin to stemoxydine as a potential treatment.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.
